Seres Therapeutics Reports Third Quarter Financial Results and Provides Operational Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Seres Therapeutics (MCRB) PT Lowered to $16 at Oppenheimer
November 9, 2018 8:57 AM ESTOppenheimer analyst Mark Breidenbach lowered the price target on Seres Therapeutics (NASDAQ: MCRB) to $16.00 (from $17.00) while maintaining a Outperform rating.
The analyst commented, "Thursday, Seres reported 3Q results and reviewed recent progress. With the appointment of a new CMO, we see... More
Seres Therapeutics (MCRB) Misses Q3 EPS by 2c, Revenues Miss
November 8, 2018 7:13 AM ESTSeres Therapeutics (NASDAQ: MCRB) reported Q3 EPS of ($0.54), $0.02 worse than the analyst estimate of ($0.52). Revenue for the quarter came in at $9 million versus the consensus estimate of $11.37 million.
Based on a growing body of promising clinical data and preclinical data from our... More
